Although asparaginase was discontinued in 76.6% of patients with AP in our study, both disease- and event-free survivals were comparable to patients who received remaining doses of ASP in the subsequent phases of therapy. The gene discussed is ASPG; the disease is alkaline phosphatase measurement.